AbbVie Shares Surge 3.28% on Strong Q2 Results and Analyst Upgrades, Trading Volume Ranks in Top 500 by Daily Trading Volume

Abbvie (ABBV) shares rose 3.28% on August 1, 2025, with a trading volume of $1.58 billion, down 20.64% from the prior day’s volume. The gain followed the company’s second-quarter results, which exceeded expectations and prompted analysts to raise price targets. Adjusted earnings per share reached $2.97, and revenue hit $15.42 billion, driven by strong sales of immunology drugs Rinvoq and Skyrizi, which offset weaker performance from older products like Humira.

Analysts at Morgan Stanley and Raymond James revised their price targets higher, citing the company’s momentum. Morgan Stanley’s Terrance Flynn raised his target to $255 from $250, while Raymond James’ Gary Nachman and Guggenheim’s Vamil Divan increased their targets to $236 and $227, respectively. All three maintained buy recommendations, emphasizing sustained demand for AbbVie’s blockbuster drugs.

The stock’s 3.28% rise outperformed the broader market, which saw the S&P 500 decline 1.6% on the same day. AbbVie’s shares remain 9.9% below their 52-week high but have gained 8.7% year-to-date. The recent analyst upgrades reflect confidence in the company’s ability to sustain growth through its key therapeutic areas.

A backtest of a strategy purchasing the top 500 stocks by daily trading volume and holding for one day returned 166.71% from 2022 to the present, significantly outperforming the 29.18% benchmark. This highlights the potential of liquidity-driven strategies in capturing short-term market movements.